Axoft has raised $8.0M in total across 1 funding round.
Axoft's investors include Boost VC, Collaborative Seed & Growth Partners, Project 11, Speedy Packets Inc., The Engine.
Axoft is a neurotechnology startup developing bio-inspired, ultra-soft brain-computer interfaces (iBCIs) that mimic brain tissue for long-term, high-resolution neural communication.[1][2][3] Its flagship product, built with proprietary Fleuron™ materials, targets patients with neurological disorders by enabling stable single-neuron measurements, signal-processing electronics, and decoding software, addressing limitations of rigid implants like tissue scarring and signal degradation.[1][2][3] The company serves healthcare providers, researchers, and industrial developers in medical devices and nanotechnology, solving the problem of short-lived brain implants that fail due to brain movement and immune responses.[1][2] Founded in 2021, Axoft raised $8 million in seed funding in 2024 led by The Engine (MIT's venture firm), fueling preclinical FDA studies, prototype scaling, and team expansion, with Fleuron materials now commercially available and more formulations planned by end-2025.[1][2][4]
Axoft was founded in 2021 in Cambridge, Massachusetts, by CEO Paul Le Floch, CTO Tianyang Ye, and scientific founder Jia Liu from Harvard's School of Engineering and Applied Sciences.[1][2] The idea emerged from Liu's research on ultra-flexible nanoelectronics that replicate the brain's mechanical properties, advanced by Le Floch during his Harvard PhD in Mechanical Engineering and Material Sciences.[2] Early traction came via Harvard's Office of Technology Development, spinning out the tech for safer brain implants to treat traumatic brain injuries and neurological conditions.[5] A pivotal moment was securing FDA Breakthrough Device designation and $8 million seed funding in 2024 from investors including The Engine, Ab Initio Capital, and others, enabling material commercialization as Fleuron™ and preclinical advancement.[1][2][4]
Axoft rides the surging brain-computer interface trend, fueled by Neuralink and Blackrock Neurotech advances, but differentiates via bio-mimicry to overcome rigid implant failures amid rising demand for neuroprosthetics treating paralysis, epilepsy, and brain injuries.[1][2] Timing aligns with FDA's push for breakthrough devices and scalable nanotech manufacturing, amplified by post-pandemic focus on chronic neurological care (affecting 1 in 6 globally).[2] Market tailwinds include aging populations, AI-driven neural decoding, and investor appetite for "tough tech" via MIT's The Engine.[2][4] Axoft influences the ecosystem by open-sourcing Fleuron for R&D, potentially standardizing biocompatible materials and enabling high-density interfaces for closed-loop therapies.[1]
Axoft is primed for rapid iteration with FDA designation, seed capital, and Fleuron sales funding human trials by 2026-2027, targeting first iBCI approvals for motor restoration or neuromodulation.[1][2] Trends like AI-enhanced decoding and hybrid bio-electronics will amplify its high-bandwidth edge, while partnerships with academics/industry could expand to vision restoration or mental health. Its influence may grow as a materials leader, licensing Fleuron to rivals and reshaping implants from rigid relics to brain-like standards—transforming neurotech from experimental to everyday clinical reality, much like its soft origins revolutionized rigid limitations.[1][3]
Axoft has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Seed in October 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2022 | $8.0M Seed | Boost VC, Collaborative Seed & Growth Partners, Project 11, Speedy Packets Inc., The Engine |
